KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents (2016 - 2025)

Exact Sciences (EXAS) has disclosed Cash & Equivalents for 16 consecutive years, with $956.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 59.1% to $956.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $956.0 million, a 59.1% increase, with the full-year FY2025 number at $956.0 million, up 59.1% from a year prior.
  • Cash & Equivalents was $956.0 million for Q4 2025 at Exact Sciences, up from $789.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q1 2021 to a low of $189.8 million in Q1 2022.
  • A 5-year average of $499.0 million and a median of $475.8 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 82.81% in 2022, then skyrocketed 183.18% in 2023.
  • Exact Sciences' Cash & Equivalents stood at $315.5 million in 2021, then dropped by 23.13% to $242.5 million in 2022, then skyrocketed by 149.65% to $605.4 million in 2023, then dropped by 0.74% to $600.9 million in 2024, then soared by 59.1% to $956.0 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Cash & Equivalents are $956.0 million (Q4 2025), $789.0 million (Q3 2025), and $657.1 million (Q2 2025).